Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study

J Am Acad Dermatol. 2022 Feb;86(2):494-497. doi: 10.1016/j.jaad.2021.10.034. Epub 2021 Oct 29.

French study Group on auto immune bullous skin diseases, and the French network of rare diseases in Dermatology (FIMARAD):
André Gillibert, Gérôme Bohelay, Karen Aouar, Saskia Ingen-Housz-Oro, Christophe Bedane, Clémence Lepelletier, Emmanuelle Tancrède Bohin, Manuelle Viguier, Nicolas Dupin, Sebastien Debarbieux, Denis Jullien, Gaelle Quereux, Cécile Morice, Antoine Mahe, Catherine Michel, Noemie Litrowski, Géraldine Jeudy, Marie Aleth Richard, Catherine Picard, Olivier Chosidow, Anne-Pham Ledard, Vivien Hebert, Sophie Duvert-Lehembre, Nadège Cordel, Marina Alexandre, Christelle Le Roux-Villet, Frédéric Caux

¹ Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and INSERM U1234, Normandie University, Rouen, France. Electronic address: Pascal.Joly@chu-rouen.fr.
² Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and INSERM U1234, Normandie University, Rouen, France.

No abstract available

Keywords: COVID-19; autoimmune bullous skin diseases; mortality; rituximab.

MeSH terms